Global Lysosomal Storage Disease (LSD) Market Size, Status and Forecast 2021-2027

リソソーム蓄積症(LSD)の世界市場規模・現状・予測2021年-2027年

◆タイトル:Global Lysosomal Storage Disease (LSD) Market Size, Status and Forecast 2021-2027
◆商品コード:QY21APR3508
◆調査・発行会社:QYResearch
◆発行日:2021年4月
◆ページ数:94
◆レポート形式:(印刷可能)PDF / 英語
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル、主要地域
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥444,600見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥666,900見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥889,200見積依頼/購入/質問フォーム
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常2日~3日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearchの日本における正規販売代理店です。

【レポートの概要】

本調査資料では、リソソーム蓄積症(LSD)の世界市場(2016年~2027年)を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模(脂質代謝異常症、糖タンパク質代謝異常症)、用途別市場規模(病院、クリニック、その他)、主要地域別市場規模(北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、企業情報などをまとめております。
・市場概要
・リソソーム蓄積症(LSD)の市場動向
・企業の競争状況、市場シェア
・リソソーム蓄積症(LSD)の種類別市場規模(脂質代謝異常症、糖タンパク質代謝異常症)
・リソソーム蓄積症(LSD)の用途別市場規模(病院、クリニック、その他)
・リソソーム蓄積症(LSD)の北米市場規模2016-2027(アメリカ、カナダ)
・リソソーム蓄積症(LSD)の欧州市場規模2016-2027(ドイツ、フランス、イギリス等)
・リソソーム蓄積症(LSD)のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等)
・リソソーム蓄積症(LSD)の中南米市場規模2016-2027(メキシコ、ブラジル)
・リソソーム蓄積症(LSD)の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等)
・主要企業情報(Actelion Pharmaceuticals、Amicus Therapeutics、Arena Pharmaceuticals、Astellas Pharma、Astrazeneca、Biomarin Pharmaceutical、Eli Lilly、Lexicon Pharmaceuticals、Novo Nordisk、Merck)
・結論

Lysosomal Storage Disease (LSD) is a genetic disorder that causes various types of nervous system disorders such as clinical abnormalities and cellular dysfunction. There are more than 65 categories of LSD. This disease can be classified into Lipid Metabolism Disorder and Glycoprotein Metabolism Disorder. Further Lipid Metabolism Disorder is categorized into Gaucher disease & Fabry disease and Glycoprotein Metabolism Disorder into Pompe disease. LSD develops mainly due to deficiency of lysosomal enzyme in the living body. A person suffering from LSD could experience problems like abnormal growth of bones, delay movement of body, deafness, blindness, dementia, respiratory problems, fatigue/weakness, bone & joint deformity, organ enlargement, lung dysfunction, severe & fatal physical & mental health deterioration.
The global LSD market is expected to grow with growing Ashkenazi (Eastern and Western Europe) population, increasing pharmaceutical R&D spending, growing disposable income, rising healthcare expenditure and accelerating economic growth. Key trends of this rare disease market includes progressing drugs under pipeline and increasing preference towards gene therapy. However, there are some factors which can hinder growth of the market including stringent regulations and limited access to patent rights.

Market Analysis and Insights: Global Lysosomal Storage Disease (LSD) Market
The global Lysosomal Storage Disease (LSD) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Lysosomal Storage Disease (LSD) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Lysosomal Storage Disease (LSD) market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Lysosomal Storage Disease (LSD) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Lysosomal Storage Disease (LSD) market.

Global Lysosomal Storage Disease (LSD) Scope and Market Size
Lysosomal Storage Disease (LSD) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Lysosomal Storage Disease (LSD) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Lipid Metabolism Disorder
Glycoprotein Metabolism Disorder

Segment by Application
Hospitals
Clinics
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Actelion Pharmaceuticals
Amicus Therapeutics
Arena Pharmaceuticals
Astellas Pharma
Astrazeneca
Biomarin Pharmaceutical
Eli Lilly
Lexicon Pharmaceuticals
Novo Nordisk

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Lysosomal Storage Disease (LSD) Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Lipid Metabolism Disorder
1.2.3 Glycoprotein Metabolism Disorder
1.3 Market by Application
1.3.1 Global Lysosomal Storage Disease (LSD) Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Lysosomal Storage Disease (LSD) Market Perspective (2016-2027)
2.2 Lysosomal Storage Disease (LSD) Growth Trends by Regions
2.2.1 Lysosomal Storage Disease (LSD) Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Lysosomal Storage Disease (LSD) Historic Market Share by Regions (2016-2021)
2.2.3 Lysosomal Storage Disease (LSD) Forecasted Market Size by Regions (2022-2027)
2.3 Lysosomal Storage Disease (LSD) Industry Dynamic
2.3.1 Lysosomal Storage Disease (LSD) Market Trends
2.3.2 Lysosomal Storage Disease (LSD) Market Drivers
2.3.3 Lysosomal Storage Disease (LSD) Market Challenges
2.3.4 Lysosomal Storage Disease (LSD) Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Lysosomal Storage Disease (LSD) Players by Revenue
3.1.1 Global Top Lysosomal Storage Disease (LSD) Players by Revenue (2016-2021)
3.1.2 Global Lysosomal Storage Disease (LSD) Revenue Market Share by Players (2016-2021)
3.2 Global Lysosomal Storage Disease (LSD) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Lysosomal Storage Disease (LSD) Revenue
3.4 Global Lysosomal Storage Disease (LSD) Market Concentration Ratio
3.4.1 Global Lysosomal Storage Disease (LSD) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Lysosomal Storage Disease (LSD) Revenue in 2020
3.5 Lysosomal Storage Disease (LSD) Key Players Head office and Area Served
3.6 Key Players Lysosomal Storage Disease (LSD) Product Solution and Service
3.7 Date of Enter into Lysosomal Storage Disease (LSD) Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Lysosomal Storage Disease (LSD) Breakdown Data by Type
4.1 Global Lysosomal Storage Disease (LSD) Historic Market Size by Type (2016-2021)
4.2 Global Lysosomal Storage Disease (LSD) Forecasted Market Size by Type (2022-2027)

5 Lysosomal Storage Disease (LSD) Breakdown Data by Application
5.1 Global Lysosomal Storage Disease (LSD) Historic Market Size by Application (2016-2021)
5.2 Global Lysosomal Storage Disease (LSD) Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Lysosomal Storage Disease (LSD) Market Size (2016-2027)
6.2 North America Lysosomal Storage Disease (LSD) Market Size by Type
6.2.1 North America Lysosomal Storage Disease (LSD) Market Size by Type (2016-2021)
6.2.2 North America Lysosomal Storage Disease (LSD) Market Size by Type (2022-2027)
6.2.3 North America Lysosomal Storage Disease (LSD) Market Size by Type (2016-2027)
6.3 North America Lysosomal Storage Disease (LSD) Market Size by Application
6.3.1 North America Lysosomal Storage Disease (LSD) Market Size by Application (2016-2021)
6.3.2 North America Lysosomal Storage Disease (LSD) Market Size by Application (2022-2027)
6.3.3 North America Lysosomal Storage Disease (LSD) Market Size by Application (2016-2027)
6.4 North America Lysosomal Storage Disease (LSD) Market Size by Country
6.4.1 North America Lysosomal Storage Disease (LSD) Market Size by Country (2016-2021)
6.4.2 North America Lysosomal Storage Disease (LSD) Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Lysosomal Storage Disease (LSD) Market Size (2016-2027)
7.2 Europe Lysosomal Storage Disease (LSD) Market Size by Type
7.2.1 Europe Lysosomal Storage Disease (LSD) Market Size by Type (2016-2021)
7.2.2 Europe Lysosomal Storage Disease (LSD) Market Size by Type (2022-2027)
7.2.3 Europe Lysosomal Storage Disease (LSD) Market Size by Type (2016-2027)
7.3 Europe Lysosomal Storage Disease (LSD) Market Size by Application
7.3.1 Europe Lysosomal Storage Disease (LSD) Market Size by Application (2016-2021)
7.3.2 Europe Lysosomal Storage Disease (LSD) Market Size by Application (2022-2027)
7.3.3 Europe Lysosomal Storage Disease (LSD) Market Size by Application (2016-2027)
7.4 Europe Lysosomal Storage Disease (LSD) Market Size by Country
7.4.1 Europe Lysosomal Storage Disease (LSD) Market Size by Country (2016-2021)
7.4.2 Europe Lysosomal Storage Disease (LSD) Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Lysosomal Storage Disease (LSD) Market Size (2016-2027)
8.2 Asia-Pacific Lysosomal Storage Disease (LSD) Market Size by Type
8.2.1 Asia-Pacific Lysosomal Storage Disease (LSD) Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Lysosomal Storage Disease (LSD) Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Lysosomal Storage Disease (LSD) Market Size by Type (2016-2027)
8.3 Asia-Pacific Lysosomal Storage Disease (LSD) Market Size by Application
8.3.1 Asia-Pacific Lysosomal Storage Disease (LSD) Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Lysosomal Storage Disease (LSD) Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Lysosomal Storage Disease (LSD) Market Size by Application (2016-2027)
8.4 Asia-Pacific Lysosomal Storage Disease (LSD) Market Size by Region
8.4.1 Asia-Pacific Lysosomal Storage Disease (LSD) Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Lysosomal Storage Disease (LSD) Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Lysosomal Storage Disease (LSD) Market Size (2016-2027)
9.2 Latin America Lysosomal Storage Disease (LSD) Market Size by Type
9.2.1 Latin America Lysosomal Storage Disease (LSD) Market Size by Type (2016-2021)
9.2.2 Latin America Lysosomal Storage Disease (LSD) Market Size by Type (2022-2027)
9.2.3 Latin America Lysosomal Storage Disease (LSD) Market Size by Type (2016-2027)
9.3 Latin America Lysosomal Storage Disease (LSD) Market Size by Application
9.3.1 Latin America Lysosomal Storage Disease (LSD) Market Size by Application (2016-2021)
9.3.2 Latin America Lysosomal Storage Disease (LSD) Market Size by Application (2022-2027)
9.3.3 Latin America Lysosomal Storage Disease (LSD) Market Size by Application (2016-2027)
9.4 Latin America Lysosomal Storage Disease (LSD) Market Size by Country
9.4.1 Latin America Lysosomal Storage Disease (LSD) Market Size by Country (2016-2021)
9.4.2 Latin America Lysosomal Storage Disease (LSD) Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Lysosomal Storage Disease (LSD) Market Size (2016-2027)
10.2 Middle East & Africa Lysosomal Storage Disease (LSD) Market Size by Type
10.2.1 Middle East & Africa Lysosomal Storage Disease (LSD) Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Lysosomal Storage Disease (LSD) Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Lysosomal Storage Disease (LSD) Market Size by Type (2016-2027)
10.3 Middle East & Africa Lysosomal Storage Disease (LSD) Market Size by Application
10.3.1 Middle East & Africa Lysosomal Storage Disease (LSD) Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Lysosomal Storage Disease (LSD) Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Lysosomal Storage Disease (LSD) Market Size by Application (2016-2027)
10.4 Middle East & Africa Lysosomal Storage Disease (LSD) Market Size by Country
10.4.1 Middle East & Africa Lysosomal Storage Disease (LSD) Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Lysosomal Storage Disease (LSD) Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Actelion Pharmaceuticals
11.1.1 Actelion Pharmaceuticals Company Details
11.1.2 Actelion Pharmaceuticals Business Overview
11.1.3 Actelion Pharmaceuticals Lysosomal Storage Disease (LSD) Introduction
11.1.4 Actelion Pharmaceuticals Revenue in Lysosomal Storage Disease (LSD) Business (2016-2021)
11.1.5 Actelion Pharmaceuticals Recent Development
11.2 Amicus Therapeutics
11.2.1 Amicus Therapeutics Company Details
11.2.2 Amicus Therapeutics Business Overview
11.2.3 Amicus Therapeutics Lysosomal Storage Disease (LSD) Introduction
11.2.4 Amicus Therapeutics Revenue in Lysosomal Storage Disease (LSD) Business (2016-2021)
11.2.5 Amicus Therapeutics Recent Development
11.3 Arena Pharmaceuticals
11.3.1 Arena Pharmaceuticals Company Details
11.3.2 Arena Pharmaceuticals Business Overview
11.3.3 Arena Pharmaceuticals Lysosomal Storage Disease (LSD) Introduction
11.3.4 Arena Pharmaceuticals Revenue in Lysosomal Storage Disease (LSD) Business (2016-2021)
11.3.5 Arena Pharmaceuticals Recent Development
11.4 Astellas Pharma
11.4.1 Astellas Pharma Company Details
11.4.2 Astellas Pharma Business Overview
11.4.3 Astellas Pharma Lysosomal Storage Disease (LSD) Introduction
11.4.4 Astellas Pharma Revenue in Lysosomal Storage Disease (LSD) Business (2016-2021)
11.4.5 Astellas Pharma Recent Development
11.5 Astrazeneca
11.5.1 Astrazeneca Company Details
11.5.2 Astrazeneca Business Overview
11.5.3 Astrazeneca Lysosomal Storage Disease (LSD) Introduction
11.5.4 Astrazeneca Revenue in Lysosomal Storage Disease (LSD) Business (2016-2021)
11.5.5 Astrazeneca Recent Development
11.6 Biomarin Pharmaceutical
11.6.1 Biomarin Pharmaceutical Company Details
11.6.2 Biomarin Pharmaceutical Business Overview
11.6.3 Biomarin Pharmaceutical Lysosomal Storage Disease (LSD) Introduction
11.6.4 Biomarin Pharmaceutical Revenue in Lysosomal Storage Disease (LSD) Business (2016-2021)
11.6.5 Biomarin Pharmaceutical Recent Development
11.7 Eli Lilly
11.7.1 Eli Lilly Company Details
11.7.2 Eli Lilly Business Overview
11.7.3 Eli Lilly Lysosomal Storage Disease (LSD) Introduction
11.7.4 Eli Lilly Revenue in Lysosomal Storage Disease (LSD) Business (2016-2021)
11.7.5 Eli Lilly Recent Development
11.8 Lexicon Pharmaceuticals
11.8.1 Lexicon Pharmaceuticals Company Details
11.8.2 Lexicon Pharmaceuticals Business Overview
11.8.3 Lexicon Pharmaceuticals Lysosomal Storage Disease (LSD) Introduction
11.8.4 Lexicon Pharmaceuticals Revenue in Lysosomal Storage Disease (LSD) Business (2016-2021)
11.8.5 Lexicon Pharmaceuticals Recent Development
11.9 Novo Nordisk
11.9.1 Novo Nordisk Company Details
11.9.2 Novo Nordisk Business Overview
11.9.3 Novo Nordisk Lysosomal Storage Disease (LSD) Introduction
11.9.4 Novo Nordisk Revenue in Lysosomal Storage Disease (LSD) Business (2016-2021)
11.9.5 Novo Nordisk Recent Development
11.10 Merck
11.10.1 Merck Company Details
11.10.2 Merck Business Overview
11.10.3 Merck Lysosomal Storage Disease (LSD) Introduction
11.10.4 Merck Revenue in Lysosomal Storage Disease (LSD) Business (2016-2021)
11.10.5 Merck Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Lysosomal Storage Disease (LSD) Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Lipid Metabolism Disorder
Table 3. Key Players of Glycoprotein Metabolism Disorder
Table 4. Global Lysosomal Storage Disease (LSD) Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Lysosomal Storage Disease (LSD) Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Lysosomal Storage Disease (LSD) Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Lysosomal Storage Disease (LSD) Market Share by Regions (2016-2021)
Table 8. Global Lysosomal Storage Disease (LSD) Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Lysosomal Storage Disease (LSD) Market Share by Regions (2022-2027)
Table 10. Lysosomal Storage Disease (LSD) Market Trends
Table 11. Lysosomal Storage Disease (LSD) Market Drivers
Table 12. Lysosomal Storage Disease (LSD) Market Challenges
Table 13. Lysosomal Storage Disease (LSD) Market Restraints
Table 14. Global Lysosomal Storage Disease (LSD) Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Lysosomal Storage Disease (LSD) Market Share by Players (2016-2021)
Table 16. Global Top Lysosomal Storage Disease (LSD) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Lysosomal Storage Disease (LSD) as of 2020)
Table 17. Ranking of Global Top Lysosomal Storage Disease (LSD) Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Lysosomal Storage Disease (LSD) Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Lysosomal Storage Disease (LSD) Product Solution and Service
Table 21. Date of Enter into Lysosomal Storage Disease (LSD) Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Lysosomal Storage Disease (LSD) Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Lysosomal Storage Disease (LSD) Revenue Market Share by Type (2016-2021)
Table 25. Global Lysosomal Storage Disease (LSD) Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Lysosomal Storage Disease (LSD) Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Lysosomal Storage Disease (LSD) Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Lysosomal Storage Disease (LSD) Revenue Market Share by Application (2016-2021)
Table 29. Global Lysosomal Storage Disease (LSD) Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Lysosomal Storage Disease (LSD) Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Lysosomal Storage Disease (LSD) Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Lysosomal Storage Disease (LSD) Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Lysosomal Storage Disease (LSD) Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Lysosomal Storage Disease (LSD) Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Lysosomal Storage Disease (LSD) Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Lysosomal Storage Disease (LSD) Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Lysosomal Storage Disease (LSD) Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Lysosomal Storage Disease (LSD) Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Lysosomal Storage Disease (LSD) Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Lysosomal Storage Disease (LSD) Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Lysosomal Storage Disease (LSD) Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Lysosomal Storage Disease (LSD) Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Lysosomal Storage Disease (LSD) Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Lysosomal Storage Disease (LSD) Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Lysosomal Storage Disease (LSD) Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Lysosomal Storage Disease (LSD) Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Lysosomal Storage Disease (LSD) Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Lysosomal Storage Disease (LSD) Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Lysosomal Storage Disease (LSD) Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Lysosomal Storage Disease (LSD) Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Lysosomal Storage Disease (LSD) Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Lysosomal Storage Disease (LSD) Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Lysosomal Storage Disease (LSD) Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Lysosomal Storage Disease (LSD) Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Lysosomal Storage Disease (LSD) Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Lysosomal Storage Disease (LSD) Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Lysosomal Storage Disease (LSD) Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Lysosomal Storage Disease (LSD) Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Lysosomal Storage Disease (LSD) Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Lysosomal Storage Disease (LSD) Market Size by Country (2022-2027) & (US$ Million)
Table 61. Actelion Pharmaceuticals Company Details
Table 62. Actelion Pharmaceuticals Business Overview
Table 63. Actelion Pharmaceuticals Lysosomal Storage Disease (LSD) Product
Table 64. Actelion Pharmaceuticals Revenue in Lysosomal Storage Disease (LSD) Business (2016-2021) & (US$ Million)
Table 65. Actelion Pharmaceuticals Recent Development
Table 66. Amicus Therapeutics Company Details
Table 67. Amicus Therapeutics Business Overview
Table 68. Amicus Therapeutics Lysosomal Storage Disease (LSD) Product
Table 69. Amicus Therapeutics Revenue in Lysosomal Storage Disease (LSD) Business (2016-2021) & (US$ Million)
Table 70. Amicus Therapeutics Recent Development
Table 71. Arena Pharmaceuticals Company Details
Table 72. Arena Pharmaceuticals Business Overview
Table 73. Arena Pharmaceuticals Lysosomal Storage Disease (LSD) Product
Table 74. Arena Pharmaceuticals Revenue in Lysosomal Storage Disease (LSD) Business (2016-2021) & (US$ Million)
Table 75. Arena Pharmaceuticals Recent Development
Table 76. Astellas Pharma Company Details
Table 77. Astellas Pharma Business Overview
Table 78. Astellas Pharma Lysosomal Storage Disease (LSD) Product
Table 79. Astellas Pharma Revenue in Lysosomal Storage Disease (LSD) Business (2016-2021) & (US$ Million)
Table 80. Astellas Pharma Recent Development
Table 81. Astrazeneca Company Details
Table 82. Astrazeneca Business Overview
Table 83. Astrazeneca Lysosomal Storage Disease (LSD) Product
Table 84. Astrazeneca Revenue in Lysosomal Storage Disease (LSD) Business (2016-2021) & (US$ Million)
Table 85. Astrazeneca Recent Development
Table 86. Biomarin Pharmaceutical Company Details
Table 87. Biomarin Pharmaceutical Business Overview
Table 88. Biomarin Pharmaceutical Lysosomal Storage Disease (LSD) Product
Table 89. Biomarin Pharmaceutical Revenue in Lysosomal Storage Disease (LSD) Business (2016-2021) & (US$ Million)
Table 90. Biomarin Pharmaceutical Recent Development
Table 91. Eli Lilly Company Details
Table 92. Eli Lilly Business Overview
Table 93. Eli Lilly Lysosomal Storage Disease (LSD) Product
Table 94. Eli Lilly Revenue in Lysosomal Storage Disease (LSD) Business (2016-2021) & (US$ Million)
Table 95. Eli Lilly Recent Development
Table 96. Lexicon Pharmaceuticals Company Details
Table 97. Lexicon Pharmaceuticals Business Overview
Table 98. Lexicon Pharmaceuticals Revenue in Lysosomal Storage Disease (LSD) Business (2016-2021) & (US$ Million)
Table 99. Lexicon Pharmaceuticals Recent Development
Table 100. Novo Nordisk Company Details
Table 101. Novo Nordisk Business Overview
Table 102. Novo Nordisk Lysosomal Storage Disease (LSD) Product
Table 103. Novo Nordisk Revenue in Lysosomal Storage Disease (LSD) Business (2016-2021) & (US$ Million)
Table 104. Novo Nordisk Recent Development
Table 105. Merck Company Details
Table 106. Merck Business Overview
Table 107. Merck Lysosomal Storage Disease (LSD) Product
Table 108. Merck Revenue in Lysosomal Storage Disease (LSD) Business (2016-2021) & (US$ Million)
Table 109. Merck Recent Development
Table 110. Research Programs/Design for This Report
Table 111. Key Data Information from Secondary Sources
Table 112. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Lysosomal Storage Disease (LSD) Market Share by Type: 2020 VS 2027
Figure 2. Lipid Metabolism Disorder Features
Figure 3. Glycoprotein Metabolism Disorder Features
Figure 4. Global Lysosomal Storage Disease (LSD) Market Share by Application: 2020 VS 2027
Figure 5. Hospitals Case Studies
Figure 6. Clinics Case Studies
Figure 7. Others Case Studies
Figure 8. Lysosomal Storage Disease (LSD) Report Years Considered
Figure 9. Global Lysosomal Storage Disease (LSD) Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global Lysosomal Storage Disease (LSD) Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Lysosomal Storage Disease (LSD) Market Share by Regions: 2020 VS 2027
Figure 12. Global Lysosomal Storage Disease (LSD) Market Share by Regions (2022-2027)
Figure 13. Global Lysosomal Storage Disease (LSD) Market Share by Players in 2020
Figure 14. Global Top Lysosomal Storage Disease (LSD) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Lysosomal Storage Disease (LSD) as of 2020
Figure 15. The Top 10 and 5 Players Market Share by Lysosomal Storage Disease (LSD) Revenue in 2020
Figure 16. Global Lysosomal Storage Disease (LSD) Revenue Market Share by Type (2016-2021)
Figure 17. Global Lysosomal Storage Disease (LSD) Revenue Market Share by Type (2022-2027)
Figure 18. North America Lysosomal Storage Disease (LSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America Lysosomal Storage Disease (LSD) Market Share by Type (2016-2027)
Figure 20. North America Lysosomal Storage Disease (LSD) Market Share by Application (2016-2027)
Figure 21. North America Lysosomal Storage Disease (LSD) Market Share by Country (2016-2027)
Figure 22. United States Lysosomal Storage Disease (LSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada Lysosomal Storage Disease (LSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Lysosomal Storage Disease (LSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Lysosomal Storage Disease (LSD) Market Share by Type (2016-2027)
Figure 26. Europe Lysosomal Storage Disease (LSD) Market Share by Application (2016-2027)
Figure 27. Europe Lysosomal Storage Disease (LSD) Market Share by Country (2016-2027)
Figure 28. Germany Lysosomal Storage Disease (LSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France Lysosomal Storage Disease (LSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. Lysosomal Storage Disease (LSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy Lysosomal Storage Disease (LSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia Lysosomal Storage Disease (LSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic Lysosomal Storage Disease (LSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Lysosomal Storage Disease (LSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Lysosomal Storage Disease (LSD) Market Share by Type (2016-2027)
Figure 36. Asia-Pacific Lysosomal Storage Disease (LSD) Market Share by Application (2016-2027)
Figure 37. Asia-Pacific Lysosomal Storage Disease (LSD) Market Share by Region (2016-2027)
Figure 38. China Lysosomal Storage Disease (LSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan Lysosomal Storage Disease (LSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea Lysosomal Storage Disease (LSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia Lysosomal Storage Disease (LSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India Lysosomal Storage Disease (LSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia Lysosomal Storage Disease (LSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Lysosomal Storage Disease (LSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Lysosomal Storage Disease (LSD) Market Share by Type (2016-2027)
Figure 46. Latin America Lysosomal Storage Disease (LSD) Market Share by Application (2016-2027)
Figure 47. Latin America Lysosomal Storage Disease (LSD) Market Share by Country (2016-2027)
Figure 48. Mexico Lysosomal Storage Disease (LSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil Lysosomal Storage Disease (LSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Lysosomal Storage Disease (LSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Lysosomal Storage Disease (LSD) Market Share by Type (2016-2027)
Figure 52. Middle East & Africa Lysosomal Storage Disease (LSD) Market Share by Application (2016-2027)
Figure 53. Middle East & Africa Lysosomal Storage Disease (LSD) Market Share by Country (2016-2027)
Figure 54. Turkey Lysosomal Storage Disease (LSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia Lysosomal Storage Disease (LSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE Lysosomal Storage Disease (LSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Actelion Pharmaceuticals Revenue Growth Rate in Lysosomal Storage Disease (LSD) Business (2016-2021)
Figure 58. Amicus Therapeutics Revenue Growth Rate in Lysosomal Storage Disease (LSD) Business (2016-2021)
Figure 59. Arena Pharmaceuticals Revenue Growth Rate in Lysosomal Storage Disease (LSD) Business (2016-2021)
Figure 60. Astellas Pharma Revenue Growth Rate in Lysosomal Storage Disease (LSD) Business (2016-2021)
Figure 61. Astrazeneca Revenue Growth Rate in Lysosomal Storage Disease (LSD) Business (2016-2021)
Figure 62. Biomarin Pharmaceutical Revenue Growth Rate in Lysosomal Storage Disease (LSD) Business (2016-2021)
Figure 63. Eli Lilly Revenue Growth Rate in Lysosomal Storage Disease (LSD) Business (2016-2021)
Figure 64. Lexicon Pharmaceuticals Revenue Growth Rate in Lysosomal Storage Disease (LSD) Business (2016-2021)
Figure 65. Novo Nordisk Revenue Growth Rate in Lysosomal Storage Disease (LSD) Business (2016-2021)
Figure 66. Merck Revenue Growth Rate in Lysosomal Storage Disease (LSD) Business (2016-2021)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed


【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[リソソーム蓄積症(LSD)の世界市場規模・現状・予測2021年-2027年] (Global Lysosomal Storage Disease (LSD) Market Size, Status and Forecast 2021-2027 / QY21APR3508)についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆